戻る Agenda
Session 8: State of the Union of Real-World Evidence (RWE) and Real-World Data (RWD): How Can we use RWD technology in the Drug Development Space? and Closing Remarks
Session Chair(s)
Keith Wenzel
Volunteer
DIA Study Endpoints Community, United States
With the continued adoption and expansion of real-world evidence (RWE) submissions being accepted by regulatory authorities, the demand for research supported by leveraging the appropriate real-world data (RWD) has facilitated the demand for higher expectations and improved best practices. This session will review today’s RWE successes and put forth the vision for where RWE is going in life sciences. Diverse RWE case studies will be presented as well as the future of RWE including insight to regulators, efficient electronic health care data extraction, RWD-driven site selection, and patient-controlled access to RWD.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify different scenarios for leveraging real-world data across the drug development spectrum
- Distinguish how realistic evolving technology and methods are such as targeted learning and EHR extraction
- Discuss patient centricity and how patients controlling access to RWD may restrict or enable clinical research
Speaker(s)
Speaker
Sanghita Bhattacharya, PhD
Johnson & Johnson Innovative Medicine, United States
Associate Director Data Science , Feasibility and Analytics, Clinical Operations
Sam Roosz, MBA
Crescendo Health, United States
Co-Founder and CEO
Speaker
Edgar Simard, PhD, MPH
Verily Life Sciences, United States
Head of Epidemiology, Biostatistics, and Data Management
Elena Izmailova, PhD
Koneksa, United States
Chief Scientific Officer